Table 2:

Univariable predictors of clinical outcome measures in patients with Crohn’s Disease

Variable	Clinical Relapse n=42† HR (95% CI), p-value	Medication escalation n=45† HR (95% CI), p-value	Corticosteroid Requirement n=32† HR (95% CI), p-value	Hospitalization for severe disease n=17† HR (95% CI), p-value
Age diagnosis of CD (years)	0.98 (0.95, 1.01), p=0.196	0.98 (0.95,1.00), p=0.127	0.98 (0.95, 1.01), p=0.204	0.98 (0.94,1.03), p=0.463
Sex (male)	0.66 (0.36, 1.23), p=0.197	0.60(0.32,1.09), p=0.095	0.65 (0.32, 1.32), p=0.239	0.49 (0.18, 1.36), p=0.171
Disease duration (years from diagnosis to colonoscopy)	0.99 (0.97, 1.02), p=0.569	0.99 (0.97,1.01), p=0.656	0.99 (0.96, 1.02), p=0.637	1.00 (0.96, 1.04), p=0.980
Penetrative vs Inflammatory (B2vsB1)	0.78 (0.39, 1.58), p=0.493	0.89 (0.44,1.76), p=0.729	1.08 (0.45, 2.59), p=0.860	1.95 (0.43, 8.90), p=0.391
Stricturing vs Inflammatory (B3vsB1)	0.44 (0.16, 1.20), p=0.111	0.45(0.17, 1.22), p=0.120	0.62 (0.19, 1.99), p=0.422	1.06 (0.17, 6.56), p=0.947
Maintenance therapy
- 5-ASA	1.21 (0.48, 3.11), p =0.682	1.13(0.44, 2.88), p=0.794	0.90 (0.27, 2.97), p=0.861	1.08 0.24, 4.76), p=0.923
- Immunomodulator	0.66 (0.35, 1.25), p=0.202	0.73(0.39, 1.36), p=0.327	0.62 (0.30, 1.27), p=0.193	0.41 (0.13, 1.25), p=0.117
On oral corticosteroids at endoscopy	1.50 (.73, 3.05), p=0.267	1.20(0.47, 3.05), p=0.703	1.34 (0.47, 3.88), p=0.578	1.29 (0.29, 5.72), p=0.737
Ongoing histological activity	2.31 (1.24, 4.31), p=0.008*	2.17(1.20, 3.96),p=0.011*	2.36 (1.16, 4.81), p=0.018*	1.27 (0.47, 3.43), p=0.636
Ongoing endoscopic activity	1.87 (1.01, 3.45), p=0.046*	1.64(0.91,2.99), p=0.102	1.39 (0.68, 2.85), p=0.369	0.97 (0.35, 2.67), p=0.951

^†Cox regression univariate analyses presented.

p Value of ≤0.05 considered significant and marked by*.

5ASA, 5-aminosalicylic acid.